Company profile
Corcept Therapeutics Incorporated
NASDAQ: CORT · Healthcare · Medical - Pharmaceuticals
#179 of 1,422 Healthcare companies by revenue59th-percentile growth
EA Score
84B+FH 88DQ 85GM 70SS 86
v0.1 · 65/100 weight · provisional
↑ Altman-Z, market scale · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$830.8M
Rev growth YoY (TTM)
+16.0%
Net income (FY)
$99.7M
Employees
730
as of 2026-08-06
Market cap
$12.0B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$761.4M$761.4M2025
Net income$99.7M$99.7M2025
Operating income$44.8M$44.8M2025
Total assets$836.7M$836.7M2025
Liabilities$188.8M$188.8M2025
Equity$647.8M$647.8M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Corcept Therapeutics Incorporated’s revenue?
Corcept Therapeutics Incorporated booked $761.4M in FY2025 revenue, growing 13% year over year — about the middle of the pack among Healthcare companies we track, at a 13.1% net margin.
Peers · Healthcare
U.S. Physical Therapy, Inc.80B+Collegium Pharmaceutical, Inc.73BAlphatec Holdings, Inc.77B+iRhythm Technologies, Inc.75B+Emergent BioSolutions Inc.69BRepligen Corporation82B+Neighbors
San Mateo →Key facts
CEOJoseph K. Belanoff
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersMenlo Park, CA
ExchangeNASDAQ: CORT
Employees730
IPO date2004-04-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.